Wesbanco Bank Inc. Grows Stock Holdings in IDEAYA Biosciences, Inc. $IDYA

Wesbanco Bank Inc. grew its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 87.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 39,700 shares of the company’s stock after purchasing an additional 18,500 shares during the period. Wesbanco Bank Inc.’s holdings in IDEAYA Biosciences were worth $1,372,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its holdings in shares of IDEAYA Biosciences by 171.1% during the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after purchasing an additional 580 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new position in IDEAYA Biosciences in the 3rd quarter worth approximately $38,000. Abich Financial Wealth Management LLC purchased a new position in IDEAYA Biosciences in the 3rd quarter worth approximately $58,000. Daiwa Securities Group Inc. raised its holdings in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after acquiring an additional 436 shares during the last quarter. Finally, Comerica Bank raised its holdings in IDEAYA Biosciences by 36.5% in the 4th quarter. Comerica Bank now owns 2,514 shares of the company’s stock worth $87,000 after acquiring an additional 672 shares during the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IDYA has been the subject of a number of recent analyst reports. Citigroup boosted their price objective on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Truist Financial set a $65.00 price objective on shares of IDEAYA Biosciences in a report on Monday, April 13th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Mizuho decreased their price objective on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Wedbush boosted their price objective on shares of IDEAYA Biosciences from $52.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Fifteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $50.69.

IDEAYA Biosciences Trading Up 0.3%

Shares of IDYA opened at $28.32 on Friday. The firm has a market cap of $2.49 billion, a PE ratio of -17.70 and a beta of -0.04. The firm has a fifty day simple moving average of $32.00 and a two-hundred day simple moving average of $32.96. IDEAYA Biosciences, Inc. has a 1-year low of $16.84 and a 1-year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. The company’s revenue was down 39.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.82) EPS. As a group, research analysts forecast that IDEAYA Biosciences, Inc. will post -4.28 EPS for the current fiscal year.

Insider Activity

In other news, Director Jeffrey Stein bought 50,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the acquisition, the director owned 54,281 shares of the company’s stock, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.50% of the stock is currently owned by insiders.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.